Latvia vs Palestine, State of: Hepatitis B surface antigen (HBsAg) prevalence
Latvia
0.0%
in 2024
Palestine, State of
0.0%
in 2024
Latvia rank
132nd
Palestine, State of rank
132nd
Hepatitis B surface antigen (HBsAg) prevalence over time
- Latvia
- Palestine, State of
How they compare
Latvia currently reports 0.0% against 0.0% in Palestine, State of, a difference of 0.0%.
The two have swapped places 2 times across 10 shared years of data; in 2015 it was Palestine, State of ahead.
Latvia ranks 132nd and Palestine, State of ranks 132nd of 194 countries.
Latvia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Latvia | Palestine, State of | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.1% | 0.0% | 0.0% | Latvia |
| 2020s | 0.0% | 0.0% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hepatitis b surface antigen (hbsag) prevalence, Latvia or Palestine, State of?
- Latvia, at 0.0% against 0.0% in Palestine, State of as of 2024.
- What is the difference in hepatitis b surface antigen (hbsag) prevalence between Latvia and Palestine, State of?
- 0.0%, with Latvia ahead.
- How many years of comparable data are there for Latvia and Palestine, State of?
- 10 years are reported by both, from 2015 to 2024.
- How do Latvia and Palestine, State of rank globally for hepatitis b surface antigen (hbsag) prevalence?
- Latvia ranks 132nd and Palestine, State of ranks 132nd of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Hepatitis B surface antigen (HBsAg) prevalence (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.